* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Saturday, August 23, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    How to watch ‘F1: The Movie’ on Prime Video – About Amazon

    Experience the Thrill: How to Stream ‘F1: The Movie’ on Prime Video

    FOX One is now available on Prime Video: Here’s everything to know – About Amazon

    FOX One is now available on Prime Video: Here’s everything to know – About Amazon

    What Are Our Predictions for Taylor Swift’s ‘Life of a Showgirl’ Based on What She’s Told Us So Far? – yahoo.com

    Uncover the Hidden Surprises in Taylor Swift’s ‘Life of a Showgirl’ – Can You Decode Her Clues?

    Bama Dining Serving Up New Food, Entertainment – UA News Center

    Bama Dining Launches Thrilling New Food and Entertainment Experiences

    The latest on Williams-Brice Stadium renovations, entertainment district – On3

    Discover the Thrilling New Upgrades Coming to Williams-Brice Stadium and Its Vibrant Entertainment District!

    1000+ Entertainment Leaders Release Open Letter Criticizing TIFF’s Handling of Film – Creative Community for Peace

    1000+ Entertainment Leaders Release Open Letter Criticizing TIFF’s Handling of Film – Creative Community for Peace

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Alcorn State awarded grant to boost STEM with VR technology – WJTV

    Alcorn State Secures Grant to Transform STEM Education Through Cutting-Edge VR Technology

    Hyundai: The Only Way To Beat China Is To Embrace Technology – InsideEVs

    Hyundai’s Bold Strategy to Outpace China with Cutting-Edge Technology

    Teaching older adults how to use technology – WWNY

    Empowering Older Adults to Master Technology with Confidence

    Denver man receives pacemaker using new technology – CBS News

    Denver Man’s Life Transformed by Revolutionary Pacemaker Technology

    Morgan County Rescue Squad is using new technology to recover people missing in the water faster – WAFF

    Morgan County Rescue Squad is using new technology to recover people missing in the water faster – WAFF

    YSU to celebrate launch of new radiology technology program – WKBN.com

    YSU Launches Exciting New Radiology Technology Program Celebration

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    How to watch ‘F1: The Movie’ on Prime Video – About Amazon

    Experience the Thrill: How to Stream ‘F1: The Movie’ on Prime Video

    FOX One is now available on Prime Video: Here’s everything to know – About Amazon

    FOX One is now available on Prime Video: Here’s everything to know – About Amazon

    What Are Our Predictions for Taylor Swift’s ‘Life of a Showgirl’ Based on What She’s Told Us So Far? – yahoo.com

    Uncover the Hidden Surprises in Taylor Swift’s ‘Life of a Showgirl’ – Can You Decode Her Clues?

    Bama Dining Serving Up New Food, Entertainment – UA News Center

    Bama Dining Launches Thrilling New Food and Entertainment Experiences

    The latest on Williams-Brice Stadium renovations, entertainment district – On3

    Discover the Thrilling New Upgrades Coming to Williams-Brice Stadium and Its Vibrant Entertainment District!

    1000+ Entertainment Leaders Release Open Letter Criticizing TIFF’s Handling of Film – Creative Community for Peace

    1000+ Entertainment Leaders Release Open Letter Criticizing TIFF’s Handling of Film – Creative Community for Peace

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Alcorn State awarded grant to boost STEM with VR technology – WJTV

    Alcorn State Secures Grant to Transform STEM Education Through Cutting-Edge VR Technology

    Hyundai: The Only Way To Beat China Is To Embrace Technology – InsideEVs

    Hyundai’s Bold Strategy to Outpace China with Cutting-Edge Technology

    Teaching older adults how to use technology – WWNY

    Empowering Older Adults to Master Technology with Confidence

    Denver man receives pacemaker using new technology – CBS News

    Denver Man’s Life Transformed by Revolutionary Pacemaker Technology

    Morgan County Rescue Squad is using new technology to recover people missing in the water faster – WAFF

    Morgan County Rescue Squad is using new technology to recover people missing in the water faster – WAFF

    YSU to celebrate launch of new radiology technology program – WKBN.com

    YSU Launches Exciting New Radiology Technology Program Celebration

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

JAK1 Inhibitor Shows ‘Remarkable’ Activity in T-Cell Lymphoma

December 16, 2023
in Health
JAK1 Inhibitor Shows ‘Remarkable’ Activity in T-Cell Lymphoma
Share on FacebookShare on Twitter

Treatment with a novel, oral JAK1 tyrosine kinase inhibitor induced rapid and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), findings from a single-arm phase II study showed.

Among 88 heavily pretreated patients evaluable for efficacy, 44% (95% CI 34-55) responded to single-agent golidocitinib, with 24% (95% CI 15-34) achieving a complete response, reported Jun Zhu, MD, of the Peking University Cancer Hospital and Institute in Beijing, and colleagues.

Moreover, the median duration of response with the selective JAK1-specific agent reached 20.7 months on independent review.

“Golidocitinib showed remarkable and durable anti-tumor activity,” the investigators concluded in Lancet Oncology. “Additionally, golidocitinib showed an acceptable and manageable safety profile in this patient population.”

In North America and Europe, PTCL accounts for about 5% to 10% of non-Hodgkin lymphoma cases, a proportion that more than doubles in Asia.

“Because of heterogenous immunophenotypes and an aggressive course of disease, there is no consensus on the standard treatment for relapsed or refractory peripheral T-cell lymphoma, and most patients have a very poor prognosis, with a 5-year survival rate lower than 30%,” wrote Zhu and co-authors.

Despite receiving accelerated approvals in relapsed or refractory PTCL, romidepsin (Istodax), pralatrexate (Folotyn), and belinostat (Beleodaq) have only shown moderate single-agent activity in this disease, according to the researchers.

In 2009, the FDA approved the histone deacetylase (HDAC) inhibitor romidepsin for PTCL, but that agent was subsequently withdrawn from the market in 2021 following a failed confirmatory trial. The agency approved the dihydrofolate reductase inhibitor pralatrexate in 2009 and the HDAC inhibitor belinostat in 2014, but neither drug has had a confirmatory trial — a source of frustration at FDA.

No JAK inhibitor is approved for PTCL, but prior research has suggested the class of agents could hold promise.

“Constitutive activation of the JAK-STAT pathway is important in T-cell malignancies,” explained Zhu and colleagues, noting that its blockade in clinical PTCL studies — with the JAK1/2 inhibitor ruxolitinib (Jakafi) and cerdulatinib, an investigational pan JAK/SYK inhibitor — has been associated with “encouraging anti-tumor activity.”

“JAK1 has been reported to be the primary driver of STAT3 phosphorylation and activation, and targeting other JAK family members is associated with increased toxicities — e.g., JAK2 inhibition-related serious anemia,” the study authors continued. “A selective JAK1 inhibitor could be a viable approach to effectively block the activation of the JAK-STAT pathway while minimizing toxicities.”

Zhu and co-authors said these phase II results will support a potential accelerated approval in PTCL. Dizal Pharmaceutical, the sponsor of golidocitinib (formerly DZD4205), has secured a fast-track designation from the FDA for speeding development and review of the agent in relapsed or refractory patients with this T-cell malignancy.

Another ongoing phase II study (NCT05963347) is evaluating golidocitinib in combination with cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisolone (CHOP); and a randomized trial is also planned to confirm the drug’s benefit in PTCL.

For the current study, investigators treated 104 adult relapsed or refractory PTCL patients across 49 centers in Australia, China, South Korea, and the U.S. with single-agent golidocitinib from 2021 to 2022. Of those, 88 were evaluable for efficacy. These patients had a median age of 58 years, 65% were men, and 94% were Asian.

PTCL not otherwise specified was the most common histologic subtype, in 57%, followed by angioimmunoblastic T-cell lymphoma in 18%, anaplastic large cell lymphoma in 11%, natural-killer T-cell lymphoma in 3%, and T-cell prolymphocytic leukemia in 1%. In the other 9%, the subtype was uncertain. Most (78%) had no bone marrow involvement at baseline, and a little more than half had increased serum lactate dehydrogenase.

Nearly three-fourths had received two or more prior lines of systemic therapy, including chemotherapy in all of the patients, an HDAC inhibitor in half, CD30-targeted therapy in 10% of the patients, and an ALK inhibitor in 1%.

Median follow-up for the current analysis was 13.3 months. Responses to golidocitinib were rapid, with a median time to first documented response of 1.4 months. The rate of radiographic complete tumor response on CT imaging was 29.5%. Beyond complete responses, 20% of patients achieved a partial response, 19% achieved stable disease, and 23% had progressive disease (14% were not evaluable).

Median progression-free survival was 5.6 months on independent review, and the estimated overall survival was 19.4 months.

In the safety cohort of all 104 patients receiving at least one dose of the JAK1 inhibitor, grade 3/4 drug-related adverse events (AEs) occurred in 59%, with the most common including decreases in neutrophil counts (29%), white blood cell counts (26%), lymphocyte counts (21%), and platelets (20%).

About a fourth of the patients had serious drug-related AEs, and three deaths occurred due to AEs of any kind (two from pneumonia and one due to confusional state).

author['full_name']

Ian Ingram is Managing Editor at MedPage Today and helps cover oncology for the site.

Disclosures

Dizal Pharmaceutical funded the study.

Zhu had no disclosures. One co-author is employed by Dizal Pharmaceutical, and other co-authors reported relationships with Dizal, Antengene, AstraZeneca, BeiGene, BostonGene, Bristol Myers Squibb, Celgene, C4 Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo, Genentech/Roche, Innate Pharmaceuticals, Kyowa Kirin, Janssen, Novartis, Seattle Genetics, Secura Bio/Verastem, and Yingli Pharmaceuticals.

Primary Source

The Lancet Oncology

Source Reference: Song Y, et al “Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study” Lancet Oncol 2023; DOI: 10.1016/S1470-2045(23)00589-2.

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/hematologyoncology/lymphoma/107871

Tags: healthInhibitorshows
Previous Post

Windsor man charged with gunpoint robbery in Tecumseh

Next Post

How to Prevent Violence Against Healthcare Workers

Crossings: How Road Ecology is Shaping the Future of Our Planet – Living on Earth

Crossings: How Road Ecology is Shaping the Future of Our Planet

August 23, 2025
Toyota Friday Night Rivals kicks off season with Elizabethton at Science Hill – WCYB

Toyota Friday Night Rivals Ignite the Season with Elizabethton vs. Science Hill Showdown

August 23, 2025
Star Trek as Refuge for the Science-Minded – The Provincetown Independent

How Star Trek Ignites Passion and Empowers the Science-Minded

August 23, 2025
Refresh your wardrobe at these 11 QTS award-winning fashion and lifestyle stores – Time Out Worldwide

Transform Your Look with These 11 Must-Visit Fashion and Lifestyle Stores

August 23, 2025
Alcorn State awarded grant to boost STEM with VR technology – WJTV

Alcorn State Secures Grant to Transform STEM Education Through Cutting-Edge VR Technology

August 23, 2025
Is Mastantuono in line for a start this Sunday? – Yahoo Sports

Is Mastantuono Set to Make His Starting Debut This Sunday?

August 23, 2025
‘Urgent action’ needed to protect workers from heat stress in warming world, UN says – Reuters

Urgent Action Needed to Shield Workers from Rising Heat Risks in a Warming World

August 22, 2025
The United States’ Biggest Vulnerability in the Trade War: Its Knowledge Economy – World Politics Review

The United States’ Greatest Weakness in the Trade War: Its Knowledge Economy

August 22, 2025
How to watch ‘F1: The Movie’ on Prime Video – About Amazon

Experience the Thrill: How to Stream ‘F1: The Movie’ on Prime Video

August 22, 2025
Willis Knighton Health in Louisiana joins Mayo Clinic Care Network – Mayo Clinic News Network

Willis Knighton Health Teams Up with Mayo Clinic Care Network to Elevate Patient Care in Louisiana

August 22, 2025

Categories

Archives

August 2025
MTWTFSS
 123
45678910
11121314151617
18192021222324
25262728293031
« Jul    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (785)
  • Economy (805)
  • Entertainment (21,684)
  • General (16,619)
  • Health (9,845)
  • Lifestyle (818)
  • News (22,149)
  • People (807)
  • Politics (814)
  • Science (16,018)
  • Sports (21,304)
  • Technology (15,786)
  • World (786)

Recent News

Crossings: How Road Ecology is Shaping the Future of Our Planet – Living on Earth

Crossings: How Road Ecology is Shaping the Future of Our Planet

August 23, 2025
Toyota Friday Night Rivals kicks off season with Elizabethton at Science Hill – WCYB

Toyota Friday Night Rivals Ignite the Season with Elizabethton vs. Science Hill Showdown

August 23, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version